Related Experiment Video
Updated: Apr 5, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Surveillance of the impact of pneumococcal conjugate vaccines in developing countries
Gail L Rodgers1, Keith P Klugman1
1a Pneumonia Program; The Bill and Melinda Gates Foundation ; Seattle , WA USA.
Insights
Pneumococcal conjugate vaccines (PCV) significantly reduce child mortality in developing nations. Monitoring vaccine-type carriage in pneumonia cases offers a feasible method to assess ongoing vaccine impact and herd effects.
Area of Science:
- Pediatrics
- Infectious Diseases
- Vaccinology
Background:
- Streptococcus pneumoniae infections are a major cause of child morbidity and mortality globally.
- Developing countries have widely adopted pneumococcal conjugate vaccines (PCV) with Gavi support.
- Early data show PCV is highly effective, providing substantial public health benefits via direct and herd effects.
Purpose of the Study:
- To assess the impact of pneumococcal conjugate vaccines (PCV) in young children.
- To explore future vaccination strategies focusing on maintaining herd immunity.
- To identify feasible methods for evaluating continued vaccine impact.
Main Methods:
- Analysis of existing data on PCV effectiveness.
- Evaluation of vaccine-type carriage in pneumonia cases.
- Assessment of direct and indirect (herd) effects of vaccination programs.
Main Results:
- PCV introduction has led to significant public health benefits.
- Vaccine effectiveness is high, contributing to reduced morbidity and mortality.
- Herd effects are a crucial component of PCV's public health impact.
Conclusions:
- Pneumococcal conjugate vaccines are highly effective in reducing child mortality.
- Future strategies may prioritize maintaining herd immunity over individual protection.
- Monitoring vaccine-type carriage in pneumonia cases is a practical approach to measure ongoing PCV impact.
Abstract:
Infection due to Streptococcus pneumoniae is a leading cause of morbidity and mortality in young children, especially in developing countries. With the support of Gavi, the Vaccine Alliance, the majority of these countries have introduced pneumococcal conjugate vaccines (PCV) into their national immunization programs and early data demonstrate a high degree of effectiveness, translating to enormous public health benefit through both direct and indirect (herd) effects. Future vaccination strategy may be focused on maintaining herd effects rather than individual protection. Evaluation of vaccine-type carriage, particularly in pneumonia cases, may be an easy, feasible way of measuring continued vaccine impact.
Related Concept Videos
Principles of Disease Surveillance
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Vaccinations
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Pneumonia III: Complications and Assessment
Vaccines

